Effect of LAPS-Exendin on Body Weight in Obese Population
Completed · Phase 2 · Has a placebo group
Conditions studied: Obesity
In brief
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Key facts
- Study ID
- NCT02075281
- Run by
- Hanmi Pharmaceutical Company Limited
- People needed
- 297
- Starts
- 2014-02-01
- Expected to finish
- 2015-02-01
- Last updated by the study team
- 2016-08-09
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.
Where it is running
- Hanmi pharmaceutical — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.